M&A / Deals Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia PharmaphorumEli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.M&A / DealsOncologyRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaphorum Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: The Omnichannel Gap: Building the CRM of the Future for Patient ServicesNext: UK Knowledge Quarter welcomes Boehringer Ingelheim AI accelerator Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
